Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GS-6624, Simtuzumab
AB0024 · 7 trials · 9 indications
The endpoints to be evaluated will include graded Adverse Events, laboratory abnormalities, and vital sign measurements
Progression free survival is measured as time from date of randomization to the earliest event time of death regardless of cause or first indication of disease progression.
Overall response for the study drug is defined by the reduction in bone marrow fibrosis score which is on a scale of 0-3 where 0 indicates the scattered linear reticulin with no fiber intersections representing normal marrow and 3 indicates dense increase in reticulin fibrosis with fiber intersections, often with osteosclerosis. Reduction from baseline of score indicates improvement in clinical condition.
To characterize the safety, tolerability, and pharmacokinetics (PK) of GS-6624 after multiple intravenous (IV) administrations in subjects with idiopathic pulmonary fibrosis (IPF).
| Arm | Type | Description |
|---|---|---|
| Treatment Arm A | EXPERIMENTAL | Simtuzumab 75 mg for 96 weeks |
| Treatment Arm B | EXPERIMENTAL | Simtuzumab 125 mg for 96 weeks |
| Treatment Arm C | PLACEBO_COMPARATOR | Placebo for 96 weeks |
| Simtuzumab in HIV Patients | EXPERIMENTAL | HIV-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV. |
| Simtuzumab in HCV Patients | EXPERIMENTAL | HCV-infected participants will receive simtuzumab every 2 weeks for 24 weeks. |
| Simtuzumab in HIV/HCV Co-Infected Patients | EXPERIMENTAL | HIV/HCV co-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV. |
| Cohort 1 | EXPERIMENTAL | Participants will receive simtuzumab at a dose of 10 mg/kg by intravenous (IV) infusion every other week for a total of 3 infusions. |
| Cohort 2 | EXPERIMENTAL | Participants will receive simtuzumab IV every other week for a total of 3 infusions. The dose will depend on the safety and tolerability of simtuzumab seen in Cohort 1 but will not exceed 20 mg/kg. |
| Simtuzumab (open-label) | EXPERIMENTAL | Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years. |
| Simtuzumab 200 mg (randomized) | EXPERIMENTAL | Participants will receive simtuzumab 200 mg plus gemcitabine in cycles of 28 days for up to 3 years. |
| Simtuzumab 700 mg (randomized) | EXPERIMENTAL | Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years. |
| Placebo (randomized) | PLACEBO_COMPARATOR | Participants will receive placebo to match simtuzumab plus gemcitabine in cycles of 28 days for up to 3 years. |
| Simtuzumab 200 mg | EXPERIMENTAL | Participants in Stage 1 of study will receive simtuzumab 200 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician. |
| Simtuzumab 700 mg | EXPERIMENTAL | Participants in Stage 1 of study will receive simtuzumab 700 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician. |
| Simtuzumab 200 mg+Ruxolitinib | EXPERIMENTAL | In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 200 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician. |
| Simtuzumab 700 mg+Ruxolitinib | EXPERIMENTAL | In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 700 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician. |
| GS-6624 125mg | EXPERIMENTAL | - |
| Experimental: GS-6624 200mg | EXPERIMENTAL | - |
| AB0024 | EXPERIMENTAL | The starting dose for Part A will be 1 mg/kg. Subsequent doses of 3, 10, and 20 mg/kg are planned. Three to 6 patients will be enrolled using a 3 + 3 design. Doses of AB0024 will be administered on Days 1, 15, 29, and 43 to characterize the safety, tolerability, and PK. The dose expansion phase of the study will begin upon completion of the dose escalation phase. Up to 20 patients will be enrolled into one or two cohorts of Part B. The first expansion cohort will be dosed up to the MTD defined as the highest dose level with an observed incidence of DLT in \<33% of patients enrolled from Part A. |
| Name | Type | Description |
|---|---|---|
| Simtuzumab | BIOLOGICAL | Subcutaneous injections weekly for a total of 96 injections |
| Placebo | BIOLOGICAL | Subcutaneous injections weekly for a total of 96 injections |
| Gemcitabine | DRUG | Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle |
| Placebo to match simtuzumab | DRUG | Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15) |
| Ruxolitinib | DRUG | In Stage 2, participants will be on a stable dose of ruxolitinib |
| GS-6624 | DRUG | Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period. |
| AB0024 | DRUG | Comparison of different dosages of drug |
Key Inclusion Criteria: * Adult Individuals (aged 18-70) with chronic cholestatic liver disease of at least 6 months. * Liver biopsy consistent with PSC: If a liver biopsy has been performed within 3 months of the screening visit, tissue from that biopsy may be used as the screening biopsy. Slides ...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
AB0024 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed by Gilead Sciences, Inc. for use in oncology, specifically in adults with advanced solid tumors.
AB0024 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical research to evaluate the safety and tolerability of this investigational small molecule in patients with advanced solid tumors.
AB0024 is in Phase 1 clinical development. It has completed a first-in-human study that evaluated its safety and tolerability in adults with advanced solid tumors. As an investigational drug, it is not yet approved by regulatory authorities and remains in clinical development.
AB0024 has been studied in one clinical trial, identified as NCT01323933, titled 'First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors.' This Phase 1 study was completed in the United States and enrolled 32 participants with neoplasms.
AB0024 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it has not received marketing approval from the U.S. Food and Drug Administration or any other regulatory agency. Its safety and efficacy have not been established for any indication.